Avelo Airlines to End DHS Deportation Flights and Close Arizona Base Amid Rising Costs 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Baidu’s AI Chip Unit Kunlunxin Prepares for Hong Kong IPO to Raise Up to $2 Billion 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Hyundai Motor Shares Surge on Nvidia Partnership Speculation 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
NEW YORK, April 05, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Cardiovascular Systems, Inc. (“Cardiovascular Systems”) (NASDAQ:CSII) between September 12, 2011 and January 21, 2016.
You are hereby notified that a securities class action has been commenced in the USDC for the Central District of California. If you purchased or otherwise acquired Cardiovascular Systems securities between September 12, 2011 and January 21, 2016, your rights may be affected by this action. To get more information go to: http://zlk.9nl.com/cardiovascular-systems.
The complaint alleges that throughout the Class Period Defendants issued false and misleading statements to investors and/or failed to disclose that: (1) Cardiovascular Systems distributed illegal kickbacks to health care providers; (2) Cardiovascular Systems engaged in the off-label promotion of its medical devices; and (3) Cardiovascular Systems violated FDA laws and regulations in connection with its medical devices. As a result of the foregoing, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Cardiovascular Systems you have until April 12, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/cardiovascular-systems.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
